JP2024026255A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024026255A5 JP2024026255A5 JP2023204313A JP2023204313A JP2024026255A5 JP 2024026255 A5 JP2024026255 A5 JP 2024026255A5 JP 2023204313 A JP2023204313 A JP 2023204313A JP 2023204313 A JP2023204313 A JP 2023204313A JP 2024026255 A5 JP2024026255 A5 JP 2024026255A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid position
- domain
- tyrosine
- binding polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000001014 amino acid Nutrition 0.000 claims 156
- 150000001413 amino acids Chemical group 0.000 claims 156
- 229920001184 polypeptide Polymers 0.000 claims 62
- 102000004196 processed proteins & peptides Human genes 0.000 claims 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims 62
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 57
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 57
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 25
- 235000003704 aspartic acid Nutrition 0.000 claims 25
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 25
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 19
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 18
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 18
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 15
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 15
- 230000002378 acidificating effect Effects 0.000 claims 14
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 12
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 12
- 235000013922 glutamic acid Nutrition 0.000 claims 12
- 239000004220 glutamic acid Substances 0.000 claims 12
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 12
- 238000006467 substitution reaction Methods 0.000 claims 12
- 230000004048 modification Effects 0.000 claims 7
- 238000012986 modification Methods 0.000 claims 7
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 6
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 4
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 3
- 239000004473 Threonine Substances 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 101000913100 Rattus norvegicus IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622468P | 2018-01-26 | 2018-01-26 | |
| US62/622,468 | 2018-01-26 | ||
| PCT/US2019/015204 WO2019147973A1 (en) | 2018-01-26 | 2019-01-25 | Fc variants with enhanced binding to fcrn and prolonged half-life |
| JP2020561607A JP7399880B2 (ja) | 2018-01-26 | 2019-01-25 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561607A Division JP7399880B2 (ja) | 2018-01-26 | 2019-01-25 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024026255A JP2024026255A (ja) | 2024-02-28 |
| JP2024026255A5 true JP2024026255A5 (enExample) | 2024-09-05 |
Family
ID=65520379
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561607A Active JP7399880B2 (ja) | 2018-01-26 | 2019-01-25 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
| JP2023204313A Pending JP2024026255A (ja) | 2018-01-26 | 2023-12-04 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561607A Active JP7399880B2 (ja) | 2018-01-26 | 2019-01-25 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190263934A1 (enExample) |
| EP (1) | EP3743441A1 (enExample) |
| JP (2) | JP7399880B2 (enExample) |
| KR (2) | KR102748986B1 (enExample) |
| CN (2) | CN119350481A (enExample) |
| AU (2) | AU2019212638B2 (enExample) |
| BR (1) | BR112020015006A2 (enExample) |
| CA (1) | CA3089602A1 (enExample) |
| CO (1) | CO2020010269A2 (enExample) |
| IL (2) | IL318916A (enExample) |
| MX (2) | MX2020007882A (enExample) |
| MY (1) | MY203898A (enExample) |
| PH (1) | PH12020551134A1 (enExample) |
| SG (1) | SG11202006905YA (enExample) |
| TW (1) | TW201940512A (enExample) |
| WO (1) | WO2019147973A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102748986B1 (ko) * | 2018-01-26 | 2025-01-02 | 젠자임 코포레이션 | FcRn에 대한 증진된 결합 및 연장된 반감기를 갖는 Fc 변이체 |
| WO2021016571A2 (en) * | 2019-07-25 | 2021-01-28 | Genzyme Corporation | Methods of treating antibody-mediated disorders with fcrn antagonists |
| CN114746120B (zh) | 2019-10-03 | 2024-07-30 | Atyr医药公司 | 包含抗nrp2抗体的组合物和方法 |
| EP4149969A1 (en) * | 2020-05-11 | 2023-03-22 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| EP4204091A2 (en) * | 2020-10-29 | 2023-07-05 | Formycon AG | Ace2 fusion proteins and uses thereof |
| MX2023014100A (es) | 2021-05-27 | 2023-12-11 | Sanofi Sa | Variante de fc con afinidad aumentada para los receptores de fc y estabilidad termica mejorada. |
| CA3227716A1 (en) | 2021-08-20 | 2023-02-23 | Intervet International B.V. | Antibodies and igg fusion proteins with an extended half-life |
| WO2023244276A2 (en) * | 2021-10-13 | 2023-12-21 | The Wistar Institute Of Anatomy And Biology | DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS |
| WO2023227790A1 (en) | 2022-05-27 | 2023-11-30 | Sanofi | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| CN116162171B (zh) * | 2022-10-13 | 2025-06-03 | 深圳市百士通科技开发有限公司 | 抗体突变方法在治疗性抗体药物中的应用 |
| KR20250094703A (ko) | 2022-10-25 | 2025-06-25 | 아블린쓰 엔.브이. | 향상된 효과기 기능을 갖는 당조작된 Fc 변이체 폴리펩타이드 |
| KR20250120344A (ko) | 2022-12-05 | 2025-08-08 | 사노피 | 트랜스페린 수용체 결합 단백질 |
| WO2025088546A1 (en) | 2023-10-25 | 2025-05-01 | Ablynx N.V. | Fc domain variants with enhanced fc receptor binding |
| WO2025101094A1 (en) * | 2023-11-08 | 2025-05-15 | Ооо «Geropharm» | Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates |
| WO2025149633A1 (en) | 2024-01-12 | 2025-07-17 | Laigo Bio B.V. | Bispecific antigen binding proteins |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994009817A1 (en) | 1992-11-04 | 1994-05-11 | City Of Hope | Novel antibody construct |
| BR9606706A (pt) | 1995-10-16 | 1999-04-06 | Unilever Nv | Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| BR0008758A (pt) * | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| AU2001270609A1 (en) | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| NZ545776A (en) | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
| WO2006031370A2 (en) * | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| BRPI0517837A (pt) | 2004-11-12 | 2008-10-21 | Xencor Inc | variantes fc com ligação alterada a fcrn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1896503B1 (en) | 2005-05-31 | 2014-10-29 | Board of Regents, The University of Texas System | IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| WO2010068722A1 (en) * | 2008-12-12 | 2010-06-17 | Medimmune, Llc | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
| US9023996B2 (en) * | 2009-12-23 | 2015-05-05 | Synimmune Gmbh | Anti-FLT3 antibodies |
| WO2011089211A1 (en) * | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
| TWI803876B (zh) | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| EP2762493B1 (en) * | 2011-09-30 | 2021-06-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| KR102266819B1 (ko) * | 2013-04-29 | 2021-06-18 | 에프. 호프만-라 로슈 아게 | Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법 |
| SI3215528T1 (sl) * | 2014-11-06 | 2019-11-29 | Hoffmann La Roche | Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe |
| WO2016075034A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| KR102777127B1 (ko) * | 2016-08-02 | 2025-03-07 | 비스테라, 인크. | 조작된 폴리펩티드 및 그의 용도 |
| KR102748986B1 (ko) * | 2018-01-26 | 2025-01-02 | 젠자임 코포레이션 | FcRn에 대한 증진된 결합 및 연장된 반감기를 갖는 Fc 변이체 |
-
2019
- 2019-01-25 KR KR1020207024432A patent/KR102748986B1/ko active Active
- 2019-01-25 CN CN202411307275.XA patent/CN119350481A/zh active Pending
- 2019-01-25 MX MX2020007882A patent/MX2020007882A/es unknown
- 2019-01-25 IL IL318916A patent/IL318916A/en unknown
- 2019-01-25 MY MYPI2020003848A patent/MY203898A/en unknown
- 2019-01-25 EP EP19707152.5A patent/EP3743441A1/en active Pending
- 2019-01-25 WO PCT/US2019/015204 patent/WO2019147973A1/en not_active Ceased
- 2019-01-25 SG SG11202006905YA patent/SG11202006905YA/en unknown
- 2019-01-25 CA CA3089602A patent/CA3089602A1/en active Pending
- 2019-01-25 IL IL276286A patent/IL276286B2/en unknown
- 2019-01-25 KR KR1020247043107A patent/KR20250008975A/ko active Pending
- 2019-01-25 AU AU2019212638A patent/AU2019212638B2/en active Active
- 2019-01-25 JP JP2020561607A patent/JP7399880B2/ja active Active
- 2019-01-25 CN CN201980015900.4A patent/CN111788221A/zh active Pending
- 2019-01-25 TW TW108102958A patent/TW201940512A/zh unknown
- 2019-01-25 BR BR112020015006-1A patent/BR112020015006A2/pt unknown
- 2019-01-25 US US16/258,080 patent/US20190263934A1/en active Pending
-
2020
- 2020-07-24 PH PH12020551134A patent/PH12020551134A1/en unknown
- 2020-07-24 MX MX2025009543A patent/MX2025009543A/es unknown
- 2020-08-20 CO CONC2020/0010269A patent/CO2020010269A2/es unknown
-
2023
- 2023-12-04 JP JP2023204313A patent/JP2024026255A/ja active Pending
-
2025
- 2025-06-26 AU AU2025204826A patent/AU2025204826A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024026255A5 (enExample) | ||
| IL276286B1 (en) | FC variants with improved binding to FCRN and extended half-life | |
| JP6435193B2 (ja) | 抗体を精製する方法 | |
| CN110382529B (zh) | 工程化的异源二聚体蛋白质 | |
| JP7566856B2 (ja) | 多重特異的抗体を調製するためのポリペプチドリンカー | |
| TWI585104B (zh) | 基於vl和vhh可變區衍生物的高親和力抗聚集抗體 | |
| CA2502904A1 (en) | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis | |
| JP2012515556A5 (enExample) | ||
| KR20120107140A (ko) | 면역글로불린 용액 정제 방법 | |
| CN113227134A (zh) | 抗体的Fc区变体 | |
| US11945839B2 (en) | Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography | |
| CN111320693B (zh) | 抗EphA4抗体 | |
| JPWO2019147973A5 (enExample) | ||
| WO2021047559A1 (zh) | 一种断裂型内含肽、使用其的重组多肽的制备方法 | |
| WO2022166728A1 (zh) | 双特异性抗体 | |
| CN106459191B (zh) | 选择具有修饰的FcRn相互作用的抗体的方法 | |
| TW202204423A (zh) | 用於產生和純化多價免疫球蛋白單可變域的方法 | |
| JP2023508366A (ja) | 二重特異性ｆｃｙｒｉｉｉ×ｃｄ３０抗体構築体の製造方法 | |
| JPWO2021016571A5 (enExample) | ||
| CN115702169A (zh) | 包含促红细胞生成素多肽的融合蛋白 | |
| JPWO2022166728A5 (enExample) | ||
| JP2022512798A (ja) | 抗体ＦｃＲｎ結合の改変 | |
| NZ767453B2 (en) | Fc variants with enhanced binding to fcrn and prolonged half-life | |
| RU2025102187A (ru) | Мутанты бычьих антител | |
| CN120225567A (zh) | 与酸性神经鞘磷脂酶蛋白特异性结合的抗体 |